Engineered immune cells take on deadly skin cancer
NCT ID NCT01955460
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 26 times
Summary
This early-phase study tests whether giving patients with advanced melanoma their own genetically modified T-cells, followed by high-dose interleukin-2, is safe and feasible. The T-cells are altered in the lab to resist a protein that normally stops them from attacking tumors. About 34 adults with stage III or IV melanoma that has spread will take part. The goal is to see if this approach can shrink tumors and control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III CUTANEOUS MELANOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.